Molecular dynamics simulations and molecular flooding studies of the retinoid X-receptor ligand binding domain

Geoffrey M. Gray, Ning Ma, Carl Wagner, Arjan van der Vaart

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Bexarotene is an FDA approved retinoid X-receptor (RXR) agonist for the treatment of cutaneous T-cell lymphoma, and its use in other cancers and Alzheimer’s disease is being investigated. The drug causes serious side effects, which might be reduced by chemical modifications of the molecule. To rationalize known agonists and to help identify sites for potential substitutions we present molecular simulations in which the RXR ligand-binding domain was flooded with a large number of drug-like molecules, and molecular dynamics simulations of a series of bexarotene-like ligands bound to the RXR ligand-binding domain. Based on the flooding simulations, two regions of interest for ligand modifications were identified: a hydrophobic area near the bridgehead and another near the fused ring. In addition, positional fluctuations of the phenyl ring were generally smaller than fluctuations of the fused ring of the ligands. Together, these observations suggest that the fused ring might be a good target for the design of higher affinity bexarotene-like ligands, while the phenyl ring is already optimized. In addition, notable differences in ligand position and interactions between the RXRα and RXRβ were observed, as well as differences in hydrogen bonding and solvation, which might be exploited in the development of subspecies-specific ligands.

Original languageEnglish (US)
Article number98
JournalJournal of Molecular Modeling
Volume23
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Retinoid X Receptors
Molecular dynamics
Ligands
molecular dynamics
ligands
Computer simulation
simulation
rings
drugs
Molecules
T-cells
Solvation
Chemical modification
Pharmaceutical Preparations
solvation
affinity
molecules
Hydrogen bonds
Substitution reactions
cancer

Keywords

  • Drug design
  • Molecular dynamics
  • Retinoid X receptor
  • Simulation

ASJC Scopus subject areas

  • Catalysis
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Computational Theory and Mathematics
  • Inorganic Chemistry

Cite this

Molecular dynamics simulations and molecular flooding studies of the retinoid X-receptor ligand binding domain. / Gray, Geoffrey M.; Ma, Ning; Wagner, Carl; van der Vaart, Arjan.

In: Journal of Molecular Modeling, Vol. 23, No. 3, 98, 01.03.2017.

Research output: Contribution to journalArticle

@article{0548c85d0ec747d3a5cfd3d9352ef8f7,
title = "Molecular dynamics simulations and molecular flooding studies of the retinoid X-receptor ligand binding domain",
abstract = "Bexarotene is an FDA approved retinoid X-receptor (RXR) agonist for the treatment of cutaneous T-cell lymphoma, and its use in other cancers and Alzheimer’s disease is being investigated. The drug causes serious side effects, which might be reduced by chemical modifications of the molecule. To rationalize known agonists and to help identify sites for potential substitutions we present molecular simulations in which the RXR ligand-binding domain was flooded with a large number of drug-like molecules, and molecular dynamics simulations of a series of bexarotene-like ligands bound to the RXR ligand-binding domain. Based on the flooding simulations, two regions of interest for ligand modifications were identified: a hydrophobic area near the bridgehead and another near the fused ring. In addition, positional fluctuations of the phenyl ring were generally smaller than fluctuations of the fused ring of the ligands. Together, these observations suggest that the fused ring might be a good target for the design of higher affinity bexarotene-like ligands, while the phenyl ring is already optimized. In addition, notable differences in ligand position and interactions between the RXRα and RXRβ were observed, as well as differences in hydrogen bonding and solvation, which might be exploited in the development of subspecies-specific ligands.",
keywords = "Drug design, Molecular dynamics, Retinoid X receptor, Simulation",
author = "Gray, {Geoffrey M.} and Ning Ma and Carl Wagner and {van der Vaart}, Arjan",
year = "2017",
month = "3",
day = "1",
doi = "10.1007/s00894-017-3260-9",
language = "English (US)",
volume = "23",
journal = "Journal of Molecular Modeling",
issn = "1610-2940",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Molecular dynamics simulations and molecular flooding studies of the retinoid X-receptor ligand binding domain

AU - Gray, Geoffrey M.

AU - Ma, Ning

AU - Wagner, Carl

AU - van der Vaart, Arjan

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Bexarotene is an FDA approved retinoid X-receptor (RXR) agonist for the treatment of cutaneous T-cell lymphoma, and its use in other cancers and Alzheimer’s disease is being investigated. The drug causes serious side effects, which might be reduced by chemical modifications of the molecule. To rationalize known agonists and to help identify sites for potential substitutions we present molecular simulations in which the RXR ligand-binding domain was flooded with a large number of drug-like molecules, and molecular dynamics simulations of a series of bexarotene-like ligands bound to the RXR ligand-binding domain. Based on the flooding simulations, two regions of interest for ligand modifications were identified: a hydrophobic area near the bridgehead and another near the fused ring. In addition, positional fluctuations of the phenyl ring were generally smaller than fluctuations of the fused ring of the ligands. Together, these observations suggest that the fused ring might be a good target for the design of higher affinity bexarotene-like ligands, while the phenyl ring is already optimized. In addition, notable differences in ligand position and interactions between the RXRα and RXRβ were observed, as well as differences in hydrogen bonding and solvation, which might be exploited in the development of subspecies-specific ligands.

AB - Bexarotene is an FDA approved retinoid X-receptor (RXR) agonist for the treatment of cutaneous T-cell lymphoma, and its use in other cancers and Alzheimer’s disease is being investigated. The drug causes serious side effects, which might be reduced by chemical modifications of the molecule. To rationalize known agonists and to help identify sites for potential substitutions we present molecular simulations in which the RXR ligand-binding domain was flooded with a large number of drug-like molecules, and molecular dynamics simulations of a series of bexarotene-like ligands bound to the RXR ligand-binding domain. Based on the flooding simulations, two regions of interest for ligand modifications were identified: a hydrophobic area near the bridgehead and another near the fused ring. In addition, positional fluctuations of the phenyl ring were generally smaller than fluctuations of the fused ring of the ligands. Together, these observations suggest that the fused ring might be a good target for the design of higher affinity bexarotene-like ligands, while the phenyl ring is already optimized. In addition, notable differences in ligand position and interactions between the RXRα and RXRβ were observed, as well as differences in hydrogen bonding and solvation, which might be exploited in the development of subspecies-specific ligands.

KW - Drug design

KW - Molecular dynamics

KW - Retinoid X receptor

KW - Simulation

UR - http://www.scopus.com/inward/record.url?scp=85014690901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014690901&partnerID=8YFLogxK

U2 - 10.1007/s00894-017-3260-9

DO - 10.1007/s00894-017-3260-9

M3 - Article

VL - 23

JO - Journal of Molecular Modeling

JF - Journal of Molecular Modeling

SN - 1610-2940

IS - 3

M1 - 98

ER -